Xeris Biopharma Holdings, Inc. (XERS): who owns it and who trades it
As of Nov 16, 2026, XERS insiders reported 35 open-market sales worth $5.8M and no purchases in the last 12 months, with 78% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin McCulloch (See Remarks), with $1.9M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Xeris Biopharma Holdings
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns XERS
239 funds and institutions reported XERS shares worth $867M at the end of Q2 2026, about 63% of the company. The largest holder is BlackRock, Inc. with 8.4%.
Funds and institutions (13F) 63%Everyone else 37%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 14.53M | 8.41% | $115M | +12% |
| D. E. Shaw & Co., Inc. | 7.80M | 4.52% | $61.8M | +0% |
| Vanguard Capital Management LLC | 7.34M | 4.25% | $58.1M | +5% |
| State Street Corp | 4.82M | 2.79% | $38.2M | +4% |
| Geode Capital Management, LLC | 4.72M | 2.73% | $37.4M | +10% |
| Nuveen, LLC | 4.39M | 2.54% | $34.7M | +50% |
| Rosalind Advisors, Inc. | 2.91M | 1.68% | $23M | -10% |
| Qube Research & Technologies Ltd | 2.89M | 1.68% | $22.9M | -30% |
| Vanguard Portfolio Management LLC | 2.63M | 1.52% | $20.8M | -1% |
| Wellington Management Group LLP | 2.37M | 1.37% | $18.7M | +9% |
| Morgan Stanley | 2.34M | 1.35% | $18.5M | -9% |
| Legal & General Group Plc | 2.01M | 1.17% | $15.9M | +5% |
| Armistice Capital, LLC | 1.96M | 1.13% | $15.5M | +3% |
| Two Sigma Investments, LP | 1.89M | 1.09% | $14.9M | -2% |
| Parkman Healthcare Partners LLC | 1.81M | 1.05% | $14.3M | +5% |
| Algert Global LLC | 1.74M | 1.01% | $13.8M | +51% |
| Northern Trust Corp | 1.60M | 0.93% | $12.7M | +11% |
| Goldman Sachs Group Inc | 1.59M | 0.92% | $12.6M | -1% |
| AQR Capital Management LLC | 1.54M | 0.89% | $12.2M | +11% |
| Charles Schwab Investment Management Inc | 1.49M | 0.86% | $11.8M | +10% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, XERS insiders reported $0 of open-market purchases and $5.8M of sales. 78% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Kevin McCulloch | See Remarks | Sale plan | 25,000 | $12.49 | $312K | Form 4 |
| Nov 2, 2026 | Beth Hecht | See Remarks | Sale plan | 25,000 | $10.23 | $256K | Form 4 |
| Nov 2, 2026 | Kevin McCulloch | See Remarks | Sale plan | 15,000 | $10.23 | $153K | Form 4 |
| Nov 2, 2026 | Steven Pieper | See Remarks | Sale plan | 5,000 | $10.23 | $51.2K | Form 4 |
| Oct 1, 2026 | Beth Hecht | See Remarks | Sale plan | 16,666 | $9.41 | $157K | Form 4 |
| Oct 1, 2026 | Kevin McCulloch | See Remarks | Sale plan | 15,000 | $9.41 | $141K | Form 4 |
| Oct 1, 2026 | Steven Pieper | See Remarks | Sale plan | 5,000 | $9.41 | $47K | Form 4 |
| Sep 28, 2026 | Kevin McCulloch | See Remarks | Sale plan | 25,000 | $10.00 | $250K | Form 4 |
| Sep 1, 2026 | Kevin McCulloch | See Remarks | Sale plan | 15,000 | $8.49 | $127K | Form 4 |
| Sep 1, 2026 | Beth Hecht | See Remarks | Sale plan | 16,666 | $8.49 | $141K | Form 4 |
| Sep 1, 2026 | Steven Pieper | See Remarks | Sale plan | 5,000 | $8.50 | $42.5K | Form 4 |
| Aug 12, 2026 | Steven Pieper | See Remarks | Sale plan | 5,000 | $8.50 | $42.5K | Form 4 |
| Aug 3, 2026 | Kevin McCulloch | See Remarks | Sale plan | 15,000 | $8.02 | $120K | Form 4 |
| Aug 3, 2026 | Beth Hecht | See Remarks | Sale plan | 16,666 | $8.01 | $133K | Form 4 |
| Jul 7, 2026 | Steven Pieper | See Remarks | Sale plan | 27,600 | $8.52 | $235K | Form 4 |
| Jul 6, 2026 | Steven Pieper | See Remarks | Sale plan | 17,400 | $8.50 | $148K | Form 4 |
| Jul 1, 2026 | Kevin McCulloch | See Remarks | Sale plan | 90,000 | $8.03 | $723K | Form 4 |
| Jul 1, 2026 | Beth Hecht | See Remarks | Sale plan | 16,666 | $8.03 | $134K | Form 4 |
| Jun 4, 2026 | Dawn Halkuff | Director | Sale plan | 20,000 | $6.09 | $122K | Form 4 |
| Jun 4, 2026 | Barbara-Jean Anne Bormann-Kennedy | Director | Sale plan | 16,000 | $6.09 | $97.4K | Form 4 |
| Jun 4, 2026 | John Johnson | Director | Sale plan | 15,000 | $6.09 | $91.3K | Form 4 |
| Jun 3, 2026 | Marla Persky | Director | Sale plan | 15,500 | $5.90 | $91.5K | Form 4 |
| Jun 1, 2026 | Beth Hecht | See Remarks | Sale plan | 16,667 | $6.06 | $101K | Form 4 |
| May 1, 2026 | Beth Hecht | See Remarks | Sale plan | 16,667 | $6.23 | $104K | Form 4 |
| Apr 1, 2026 | Beth Hecht | See Remarks | Sale plan | 16,667 | $5.99 | $99.8K | Form 4 |
| Mar 30, 2026 | James Aloysius Brady | Director | Sale plan | 10,834 | $5.54 | $60K | Form 4 |
| Mar 2, 2026 | Beth Hecht | See Remarks | Sale plan | 16,567 | $6.24 | $103K | Form 4 |
| Mar 2, 2026 | Beth Hecht | See Remarks | Sale plan | 100 | $7.06 | $706 | Form 4 |
| Feb 2, 2026 | Beth Hecht | See Remarks | Sale | 16,667 | $7.45 | $124K | Form 4 |
| Jan 8, 2026 | Kevin McCulloch | See Remarks | Sale plan | 15,000 | $8.00 | $120K | Form 4 |
| Jan 5, 2026 | John Patrick Shannon Jr | Director | Sale | 24,907 | $7.08 | $176K | Form 4 |
| Jan 2, 2026 | Beth Hecht | See Remarks | Sale plan | 16,667 | $7.43 | $124K | Form 4 |
| Dec 19, 2025 | John Johnson | Director | Sale | 135,400 | $7.22 | $978K | Form 4 |
| Dec 12, 2025 | Barbara-Jean Anne Bormann-Kennedy | Director | Sale plan | 15,000 | $7.09 | $106K | Form 4 |
| Dec 1, 2025 | Beth Hecht | See Remarks | Sale plan | 16,667 | $7.01 | $117K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kevin McCulloch | See Remarks | – | $1.9M | Nov 5, 2026 |
| Beth Hecht | See Remarks | – | $1.6M | Nov 2, 2026 |
| John Johnson | Director | – | $1.1M | Jun 4, 2026 |
| Steven Pieper | See Remarks | – | $566K | Nov 2, 2026 |
| Barbara-Jean Anne Bormann-Kennedy | Director | – | $204K | Jun 4, 2026 |
| John Patrick Shannon Jr | See Remarks, Director | – | $176K | Jan 5, 2026 |
| Dawn Halkuff | Director | – | $122K | Jun 4, 2026 |
| Marla Persky | Director | – | $91.5K | Jun 3, 2026 |
| James Aloysius Brady | Director | – | $60K | Mar 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
XERS short interest
Low short interest. 4.9% of XERS shares are sold short: about 1 share in 20. Over the last 12 reports the number of shares short went down 27%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.99M XERS shares were sold short, 4.9% of the shares outstanding, up 11.9% from the report before. At the average daily volume of 2.07M shares, buying them all back would take about 4.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.99M | 4.93% | +12% | 2.07M | 4.3 |
| Oct 15, 2026 | 8.03M | 4.40% | +11% | 2.46M | 3.3 |
| Sep 30, 2026 | 7.20M | 3.95% | -11% | 4.15M | 1.7 |
| Sep 15, 2026 | 8.06M | 4.42% | +0% | 1.67M | 4.8 |
| Aug 31, 2026 | 8.04M | 4.41% | -8% | 1.47M | 5.5 |
| Aug 14, 2026 | 8.73M | 4.79% | -5% | 1.97M | 4.4 |
| Jul 31, 2026 | 9.22M | 5.06% | -9% | 1.37M | 6.8 |
| Jul 15, 2026 | 10.08M | 5.84% | -21% | 2.30M | 4.4 |
| Jun 30, 2026 | 12.76M | 7.39% | -0% | 2.34M | 5.4 |
| Jun 15, 2026 | 12.81M | 7.42% | +2% | 1.75M | 7.3 |
| May 29, 2026 | 12.51M | 7.25% | +1% | 1.33M | 9.4 |
| May 15, 2026 | 12.36M | 7.16% | -22% | 2.13M | 5.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Xeris Biopharma Holdings company events
Xeris Biopharma Holdings filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Nov 2, 2026LeadershipThe Board of Directors of Xeris Biopharma Holdings, Inc. increased the size of the Board from eight (8) to nine (9) members, thereby creating a vacancy on the Board, and appointed Menassie Taddese to fill such vacancy. Filing
- Oct 14, 2026AnnouncementXeris Biopharma Holdings, Inc., through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey against defendants (i) Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals… Filing
- Sep 9, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 17, 2026AnnouncementBelow with respect to the Shares (as defined herein) is incorporated into this Item 3.02 by reference, insofar as it relates to the unregistered sales of equity securities. Filing
- Jun 30, 2026LeadershipThe Board of Directors of Xeris Biopharma Holdings, Inc. increased the size of the Board from seven (7) to eight (8) members, thereby creating a vacancy on the Board, and appointed Nerissa Kreher, M.D., to fill such vacancy, effective as of July 1, 2026. Filing
- Jun 11, 2026AnnouncementThe Company issued a press release announcing entry into the Exchange Agreements. Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 21, 2026LeadershipDr. Jeffrey Sherman, a member of the Board of Directors of Xeris Biopharma Holdings, Inc., provided notice to the Company of his decision to retire from the Board and not stand for reelection at the Company’s 2026 Annual Meeting of Stockholders. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Feb 27, 2026AnnouncementShared information with investors. Filing
- Jan 8, 2026ResultsReleased financial results. Filing
- Dec 1, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Xeris Biopharma Holdings financials
Famous investors that hold XERS
4 of the 50 well-known investors we track reported holding XERS in their latest 13F filing. The largest position is Steve Cohen's, worth $20.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 2.13M | $20.3M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 277,664 | $2.7M | 0.0% | +1152% |
| Israel Englander · Millennium Management | Q3 2026 | 245,814 | $2.3M | 0.0% | +87% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 169,287 | $1.6M | 0.0% | -75% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named XERS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 5.0% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 5.0% |
Questions about Xeris Biopharma Holdings, Inc. (XERS) stock
Who owns the most XERS stock?
The largest reported owner of Xeris Biopharma Holdings, Inc. (XERS) is BlackRock, Inc., with 8.4% of the company. In total, 239 funds and institutions reported holding XERS at the end of Q2 2026, together about 63% of the shares. See the largest owners.
Are XERS insiders buying or selling?
In the last 12 months, XERS insiders reported no open-market purchases and 35 sales worth $5.8M. The latest trade was on Nov 5, 2026. See every trade.
What is the short interest in XERS?
As of Oct 30, 2026, 8.99M XERS shares were sold short, 4.9% of the shares outstanding, up 11.9% from the report before. At the average daily volume of 2.07M shares, buying them all back would take about 4.3 trading days (days to cover). See the history.
Which famous investors hold XERS?
4 of the 50 well-known investors we track reported XERS in their latest 13F filing, including Steve Cohen, Paul Tudor Jones, Israel Englander. The largest position is worth $20.3M. See all holders.
Executive pay
Xeris Biopharma Holdings's chief executive was paid a total of $5M for the year ended Dec 31, 2025. In the last 12 months, Xeris Biopharma Holdings's executives and directors bought no stock on the open market and sold $6M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.